HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of intravenous stilbestrol diphosphate in patients with prostatic carcinoma refractory to conventional hormonal manipulation.

Abstract
The patient presenting with severe bone pain after primary hormonal therapy, with vertebral collapse, or with uremia resulting from ureteric obstruction should be considered for intravenous stilbestrol diphosphate therapy. The urologist can expect early marked improvement in the patients' mobility and pain, with a reduction in analgesic requirements, from a single 7-day course of treatment. In addition, the drug is inexpensive and free of the side effects commonly associated with cytotoxic therapy. Accurate monitoring of the response is possible with serum prostate-specific antigen measurements, which also enable further therapy to be planned efficiently.
AuthorsM A Ferro
JournalThe Urologic clinics of North America (Urol Clin North Am) Vol. 18 Issue 1 Pg. 139-43 (Feb 1991) ISSN: 0094-0143 [Print] United States
PMID1992567 (Publication Type: Journal Article)
Chemical References
  • Diethylstilbestrol
  • fosfestrol
Topics
  • Diethylstilbestrol (administration & dosage, adverse effects, analogs & derivatives, pharmacology, therapeutic use)
  • Humans
  • Male
  • Pain
  • Prostatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: